Rubric Capital Management (New York)’s scPharmaceuticals SCPH Stock Holding History

Rubric Capital Management (New York)’s Portfolio SCPH Stock Details SCPH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-5,101,886	Closed	-$28.9M	–	84
2025 Q3	$28.9M	Buy	5,101,886 +499,909	+11%	+$2.56M	0.33%	50
2025 Q2	$17.5M	Sell	4,601,977 -173,023	-4%	-$537K	0.26%	53
2025 Q1	$12.6M	Hold	4,775,000	–	–	0.23%	50
2024 Q4	$16.9M	Hold	4,775,000	–	–	0.22%	52
2024 Q3	$21.8M	Buy	4,775,000 +1,250,000	+35%	+$6.05M	0.35%	46
2024 Q2	$15.3M	Hold	3,525,000	–	–	0.4%	48
2024 Q1	$17.7M	Buy	3,525,000 +25,000	+0.7%	+$140K	0.52%	49
2023 Q4	$21.9M	Buy	3,500,000 +786,713	+29%	+$4.51M	0.46%	36
2023 Q3	$19.3M	Buy	2,713,287 +1,901,770	+234%	+$15M	0.72%	36
2023 Q2	$8.27M	Buy	+811,517	New	+$8.47M	0.35%	49

Rubric Capital Management (New York)'s SCPH Position: Q4 2025 in Review

Rubric Capital Management (New York) sold out of scPharmaceuticals (SCPH) in Q4 2025, closing a stake of 5,101,886 shares — an estimated $28.9M sold.

Rubric Capital Management (New York) first reported a position in SCPH in Q2 2023 and held it in 10 quarters. The position peaked at $28.9M in Q3 2025. 0 funds tracked by Wall St. Rank hold SCPH as of Q4 2025.

Rubric Capital Management (New York) reported no remaining scPharmaceuticals position as of Q4 2025 after selling out during the quarter.
Rubric Capital Management (New York) sold 5,101,886 scPharmaceuticals shares in Q4 2025, an estimated $28.9M.
Rubric Capital Management (New York) first reported a position in scPharmaceuticals in Q2 2023 and held it in 10 quarters.
Rubric Capital Management (New York)'s scPharmaceuticals position peaked at $28.9M in Q3 2025.
0 funds tracked by Wall St. Rank held scPharmaceuticals as of Q4 2025.

Based on Rubric Capital Management (New York)'s 13F filing for Q4 2025, filed 13 Feb 2026.